Literature DB >> 10583179

Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous rheumatoid nodule.

D A Vardy1, A Cohen, L Kachko, A Zvulunov, S Frankenburg.   

Abstract

Cutaneous leishmaniasis is a protozoal infection generally considered to be limited to the skin. In Israel, the disease is common in geographically defined areas and is caused predominantly by Leishmania major. Sporotrichoid subcutaneous spread has been reported but is uncommon. We describe a patient with rheumatoid arthritis, treated with methotrexate and prednisone, in whom numerous rheumatoid nodules concomitant with cutaneous leishmaniasis were found, mimicking sporotrichoid spread of the disease. In a rheumatoid nodule that was examined by electron microscopy, Leishmania parasites were found at intracellular and extracellular locations. This observation supports the hypothesis that cutaneous leishmaniasis parasites persist after clinical cure of the disease and may re-emerge as a result of immunosuppression.

Entities:  

Mesh:

Year:  1999        PMID: 10583179     DOI: 10.1046/j.1365-2133.1999.03169.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

Review 1.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 2.  [Common tropical infections with protozoans, worms and ectoparasites].

Authors:  S Schliemann
Journal:  Hautarzt       Date:  2014-10       Impact factor: 0.751

Review 3.  Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Authors:  Ioannis D Xynos; Maria G Tektonidou; Dimitrios Pikazis; Nikolaos V Sipsas
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

4.  Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity.

Authors:  Susana Mendez; Stacie K Reckling; Ciriacco A Piccirillo; David Sacks; Yasmine Belkaid
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.